Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MG 4101

Next Previous
Drug Profile

MG 4101

Alternative Names: Allogeneic natural killer cells – GC Biopharma; Allogeneic NK cells; MG-4101

Latest Information Update: 01 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Green Cross
  • Developer GC Biopharma; Samsung Medical Center; Seoul National University Hospital
  • Class Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Liver cancer; Solid tumours
  • Phase I/II Non-Hodgkin's lymphoma
  • No development reported Lymphoma

Most Recent Events

  • 29 Mar 2022 GC Pharma is now called GC Biopharma
  • 11 Dec 2021 Safety and efficacy data from a phase II trial in Acute myeloid leukaemia presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2021)
  • 05 Dec 2020 Efficacy and adverse events data from a phase I/II trial in Non-Hodgkin's lymphoma presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem 2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top